findmyKOL
Clinical trialNCT01415765WithdrawnPhase 1/PHASE2Interventional

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment0Diffuse, Large B-cell LymphomaLarge-Cell Lymphoma, DiffuseLymphoma, Diffuse Large-CellLymphoma, Diffuse Large-Cell B-cell
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Background: \- MLN4924 is an experimental cancer drug. It may help kill lymphoma cells and make them more sensitive to chemotherapy. EPOCH R is a combination chemotherapy drug. It has been effective in treating some cases of large B-cell lymphoma. This research will look at two things. The first is the effect of MLN4924 on its own in treating large B-cell lymphoma. The second is the safe dose and effect of MLN4924 and EPOCH-R in combination when treating large B-cell lymphoma. Objectives: * To study how MLN4924 affects large B-cell lymphoma tumors. * To compare the effects of MLN 4924 alone and MLN4924 plus standard EPOCH-R chemotherapy. Eligibility: \- Individuals at least 18 years of age who have large B-cell lymphoma that will be treated with chemotherapy. Design: * Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, tumor samples, and imaging studies. * Participants will receive MLN4924 for a maximum of six 21-day cycles of treatment. Each cycle involves a dose of MLN4924 twice a week for 2 weeks, followed by a 1-week rest period. Participants will be monitored with frequent blood tests and imaging studies. * Participants who do not benefit from MLN4924 alone will have MLN4924 along with EPOCH-R chemotherapy for up to six cycles of treatment.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Doxorubicin →Etoposide →Filgrastim →MLN4924Prednisone →Rituximab →Vincristine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Jul 2011
Primary completion
7 Jan 2014
Completion
7 Jan 2014
Last update posted
17 Dec 2019
Registered enrollment
0
Registry id
NCT01415765
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.